- Home
- GNTA vs FLNA Comparison
GNTA vs FLNA Comparison
Compare GNTA & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | FLNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 61.8M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GNTA | FLNA |
|---|---|---|
| Price | $0.99 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.0K | ★ 227.1K |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.80 |
| 52 Week High | $10.00 | $2.03 |
Technical Indicators
Market Signals| Indicator | GNTA | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 30.18 |
| Support Level | $0.58 | N/A |
| Resistance Level | $1.70 | $0.99 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.68 | 20.14 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.